John G Ullman & Associates Inc. lessened its holdings in Baxter International Inc (NYSE:BAX) by 22.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 76,577 shares of the medical instruments supplier’s stock after selling 22,431 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Baxter International were worth $4,950,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in BAX. Acadian Asset Management LLC lifted its stake in shares of Baxter International by 156.7% in the fourth quarter. Acadian Asset Management LLC now owns 657,855 shares of the medical instruments supplier’s stock worth $42,523,000 after buying an additional 401,532 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in shares of Baxter International by 35.8% in the third quarter. Canada Pension Plan Investment Board now owns 1,413,054 shares of the medical instruments supplier’s stock worth $88,669,000 after buying an additional 372,500 shares in the last quarter. Segall Bryant & Hamill LLC lifted its stake in shares of Baxter International by 209.0% in the third quarter. Segall Bryant & Hamill LLC now owns 412,054 shares of the medical instruments supplier’s stock worth $25,856,000 after buying an additional 278,685 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Baxter International by 619.2% in the third quarter. Nordea Investment Management AB now owns 188,842 shares of the medical instruments supplier’s stock worth $11,850,000 after buying an additional 162,584 shares in the last quarter. Finally, AustralianSuper Pty Ltd bought a new position in shares of Baxter International in the third quarter worth approximately $9,871,000. Institutional investors and hedge funds own 83.81% of the company’s stock.

Shares of Baxter International Inc (BAX) traded up $0.05 during trading on Wednesday, reaching $71.80. 155,333 shares of the company were exchanged, compared to its average volume of 2,959,124. The company has a market capitalization of $39,255.14, a P/E ratio of 38.69, a price-to-earnings-growth ratio of 2.19 and a beta of 0.69. Baxter International Inc has a 12 month low of $46.68 and a 12 month high of $72.49. The company has a current ratio of 2.80, a quick ratio of 2.22 and a debt-to-equity ratio of 0.37.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 1st were given a dividend of $0.16 per share. The ex-dividend date was Thursday, November 30th. This represents a $0.64 dividend on an annualized basis and a yield of 0.89%. Baxter International’s dividend payout ratio (DPR) is 34.41%.

In related news, SVP Giuseppe Accogli sold 28,641 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total transaction of $1,918,947.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Third Point Llc sold 5,000,000 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $64.23, for a total transaction of $321,150,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,061,991 shares of company stock worth $325,245,035. 0.05% of the stock is owned by insiders.

Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Baxter International from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. Evercore ISI assumed coverage on shares of Baxter International in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $71.00 target price on the stock. Raymond James Financial upgraded shares of Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 target price on the stock in a research note on Wednesday, January 3rd. Stifel Nicolaus reiterated a “hold” rating and issued a $65.00 target price on shares of Baxter International in a research note on Thursday, October 26th. Finally, JPMorgan Chase & Co. upgraded shares of Baxter International from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 2nd. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Baxter International presently has an average rating of “Buy” and a consensus price target of $68.64.

ILLEGAL ACTIVITY NOTICE: “John G Ullman & Associates Inc. Sells 22,431 Shares of Baxter International Inc (BAX)” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://theolympiareport.com/2018/01/31/john-g-ullman-associates-inc-sells-22431-shares-of-baxter-international-inc-bax.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.